Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Tizona Therapeutics

Tizona Therapeutics
2014 FOUNDED
PRIVATE STATUS
21-30 EMPLOYEES
Series B3 LATEST DEAL TYPE
$15M LATEST DEAL AMOUNT
9 INVESTORS
Description

Developer of cancer immunotherapy treatments designed to harness the power of the immune system to develop treatments for cancer and autoimmune diseases. The company's treatments are designed to modulate the activity of immunosuppressive cells by targeting the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment, enabling cancer patients to achieve complete, durable remissions and help patients to live longer.

Formerly Known As
Vesuvius Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 4000 Shoreline Court
  • Suite 200
  • South San Francisco, CA 94080
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Tizona Therapeutics’s full profile, request a free trial.

Tizona Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Early Stage VC (Series B3) 10-Jan-2019 $15M 00000 00000 Completed Clinical Trials - Phase 1
6. Corporate 03-Jan-2019 00000 00000 Completed Clinical Trials - Phase 1
5. Debt - General 06-Sep-2018 0000 00000 Completed Pre-Clinical Trials
4. Early Stage VC (Series B2) 04-Aug-2017 0000 0000 0000 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 23-Feb-2016 0000 0000 000.00 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 17-Sep-2015 $27M $27M 0000 Completed Startup
1. Accelerator/Incubator 31-Jul-2015 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Tizona Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B3 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 0.000
Series B2 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series B 13,333,332 $0.000100 $0.01 $1.5 $1.5 1x $1.5 13.33%
Series A 27,217,500 $0.000100 $0.08 $1 $1 1x $1 27.22%
To view this company’s complete Cap Table, request access »

Tizona Therapeutics Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immatics Venture Capital-Backed Tübingen, Germany 00 00000 00000000000 00000
000000000 Venture Capital-Backed Rockville, MD 000.00 0000000000 0 000.00
000 000000000000 Formerly VC-backed Boston, MA 0000 000000&0 0000
00000000000 Angel-Backed Culver City, CA 00000 000000000000 00000
00000000 Formerly VC-backed Munich, Germany 000.00 000000&0 000.00
To view this company’s complete list of competitors, request access »

Tizona Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
AbbVie Corporation Minority 000 0000 000000 0
Abingworth Management Venture Capital Minority 000 0000 000000 0
Canaan Partners Venture Capital Minority 000 0000 000000 0
Lightstone Ventures Venture Capital Minority 000 0000 000000 0
Amgen Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Tizona Therapeutics Executive Team (21)

Name Title Board
Seat
Contact
Info
Scott Clarke Chief Executive Officer & Board Member
Shelly Pinto Controller & Vice President, Finance
Mark Smyth Ph.D Advisor Board Member & Scientific Co-Founder
Courtney Beers Ph.D Vice President, Immunology
John Corbin Ph.D Vice President of Antibody Development

8 Former Executives

You’re viewing 5 of 21 executives. Get the full list »

Tizona Therapeutics Board Members (13)

Name Representing Role Since Contact
Info
Daniel Hicklin Ph.D MPM Capital Board Member 000 0000
KT Moortgat Ph.D Self Board Member 000 0000
Luke Evnin Ph.D MPM Capital Chairman 000 0000
Nina Kjellson Canaan Partners Board Member 000 0000
Pablo Cagnoni MD MPM Capital Board Member 000 0000

6 Former Board Members

You’re viewing 5 of 13 board members. Get the full list »